MedTrace Logo

Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion

NCT03151746 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-07-21

Study results available
· View outcomes & findings →

Summary

The study's objective is to determine the efficacy of preoperative gabapentin in relieving postoperative pain, reducing opioid use and improving quality of recovery in subjects undergoing urologic surgery.

Investigators hypothesize that subjects receiving gabapentin will have lower pain scores, less opioid consumption and better quality of recovery as compared to subjects who are given a placebo.

Conditions

  • Anesthesia
  • Urethral Obstruction

Interventions

DRUG

Placebo

Placebo pill administered orally 1 hour before planned surgical procedure

DRUG

Gabapentin

Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure

Sponsors & Collaborators

Principal Investigators

  • Luminita Tureanu, M.D. · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-14
Primary Completion
2021-12-02
Completion
2021-12-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03151746 on ClinicalTrials.gov